Durable PSA Control After Testosterone Recovery in High‑Risk Biochemical Recurrent Prostate Cancer

A recent post hoc analysis of the phase 3 EMBARK trial in high‑risk biochemical recurrent prostate cancer has generated considerable interest because it suggests that durable, long‑term PSA control can occur even after testosterone has fully recovered to eugonadal levels, challenging the conventional assumption that hormonal suppression must be continuous to maintain remission. The analysis builds on the original EMBARK results, which evaluated enzalutamide plus leuprolide, enzalutamide monotherapy, and leuprolide alone in men with high‑risk, non‑metastatic biochemical recurrence after radical prostatectomy and/or radiation, defined by a PSA doubling time of 9 months or less and no evidence of metastases. A distinctive feature of the trial design was that treatment was suspended at week 37 in patients whose PSA fell below 0.2 ng/mL, with the option to resume therapy if PSA later rose to protocol‑defined thresholds.

Following treatment suspension, the majority of patients experienced complete or near‑complete recovery of serum testosterone, with more than 80% achieving levels above commonly used thresholds for normal testosterone and over 95% showing at least partial recovery, indicating that the gonadal axis is largely preserved in this setting, even after finite‑duration androgen‑receptor pathway inhibition combined with gonadotropin‑releasing‑hormone agonist therapy. This pattern of recovery is clinically important because it supports the feasibility of treatment‑holiday strategies aimed at reducing the cumulative burden of hypogonadism and its associated morbidity while still relying on intermittent hormonal control.

Against this backdrop, the new analysis focuses on a subset of patients who maintained a PSA level below 0.2 ng/mL for extended periods, sometimes several years, despite testosterone having returned to supracastrate concentrations, including values above 250 ng/dL. In this group, which represented a small proportion of the overall cohort (around 3–4%), the observation of deep, off‑therapy PSA suppression suggests that the finite course of intensive hormonal therapy may have induced a biologically meaningful “reset” or prolonged remission state in selected individuals, even after the restoration of physiologic androgen levels. Patients who initially received the enzalutamide plus leuprolide combination appeared overrepresented in this subgroup, hinting that the intensity and duration of androgen‑receptor targeting early in the hormonal‑sensitive window may shape the durability of PSA control once treatment is interrupted.

From a clinical perspective, these findings raise the possibility that hormonal therapy alone, carefully timed and delivered in a finite fashion, can occasionally produce long‑term biochemical remissions in men with high‑risk biochemical recurrence, even when not delivered continuously. This does not mean that all patients can or should expect such a durable outcome, but it does support further investigation into predictors of sustained PSA suppression such as baseline PSA, PSA kinetics, pretreatment testosterone, prior local therapy, and genomic or imaging features, that might help distinguish those most likely to experience prolonged remission from those who will need earlier or more continuous systemic control.

Source.